Project Grant K99CA312801
Award Date 7/1/26
Completion Date 6/30/38
Dollars Obligated $110K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
- Federal Grant Award Summary Duke University's Office of Research Administration received a $120,403 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective June 1, 2026 through May 31, 2027. The award supports the development and implementation of ultrasensitive maximum depth sequencing (MDS) technology to detect occult residual pancreatic cancer disease in patients eligible for curative surgical resection. The research...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $100,228 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2026, with completion targeted for April 30, 2028. The award funds the development of a verifiable and robust deformable image registration (DIR) method to advance precision tracking of diffuse glioma progression, particularly glioblastoma (GBM). The project addresses a...
- Federal Grant Award Summary Duke University, in Durham, North Carolina, received a $402,135 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) for the period of May 1, 2026 through April 30, 2029. The award supports development and optimization of SCHICAR (Single-Cell Hi-C and Chromatin Accessibility and RNA), a novel single-cell multi-omics platform that simultaneously captures three critical data modalities: three-dimensional (3D) genome...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on April 24, 2026, with completion targeted for March 31, 2028. This research initiative focuses on modeling minimal residual disease (MRD) in colorectal cancer patients to identify and characterize cancer cells that persist after primary tumor resection. The project employs novel...
- Federal Project Grant Award Summary Duke University's Office of Research Administration has been awarded $1.88M in federal funding by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research integrating genome-wide association study (GWAS) data with single-cell omics technologies to identify cellular effectors of glioblastoma predisposition. The project, initiated on September 23, 2025, and scheduled for completion by August 31,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Duke University $302,524 through the Cancer Research Manpower program (CFDA 93.398) on September 10, 2025, to support a postdoctoral fellowship research project investigating SMARCAL1 depletion and its role in enhancing immunogenicity in Alternative Lengthening of Telomeres (ALT)-positive high-grade gliomas. The project, which extends through April 30, 2028, will deliver research services encompassing both in vitro...
- Federal Grant Award Summary Duke University's Office of Research Administration has been awarded $395,846 by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the project period April 1, 2026 through March 31, 2031. This Project Grant supports research on therapeutic targeting of SMARCAL1 (an annealing helicase protein) as a synthetic lethal vulnerability in alternative lengthening of telomeres (ALT)-positive cancers, particularly IDH-mutant...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded September 23, 2025, with completion targeted for August 31, 2029. The project delivers development and validation of a Virtual Preclinical CT (VPCT) platform designed as a digital twin for preclinical cancer modeling of head and neck squamous cell carcinoma...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $607,157 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026, through April 30, 2031. The award funds fundamental cancer biology research focused on defining the role of tyrosine threonine kinase (TTK), also known as monopolar spindle 1 (MPS1), in neuroendocrine prostate cancer (NEPC). The research addresses an urgent...